KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Bio-Rad Laboratories (BIO) Net Margin (2016 - 2026)

Bio-Rad Laboratories has reported Net Margin over the past 18 years, most recently at 89.02% for Q1 2026.

  • Quarterly Net Margin fell 9995.0% to 89.02% in Q1 2026 from the year-ago period, while the trailing twelve-month figure was 6.52% through Mar 2026, up 9168.0% year-over-year, with the annual reading at 29.42% for FY2025, 10127.0% up from the prior year.
  • Net Margin was 89.02% for Q1 2026 at Bio-Rad Laboratories, down from 103.87% in the prior quarter.
  • Over five years, Net Margin peaked at 113.35% in Q4 2022 and troughed at 480.98% in Q1 2022.
  • The 5-year median for Net Margin is 10.19% (2023), against an average of 51.68%.
  • Year-over-year, Net Margin tumbled -61546bps in 2022 and then skyrocketed 49117bps in 2023.
  • A 5-year view of Net Margin shows it stood at 113.35% in 2022, then crashed by -55bps to 51.34% in 2023, then plummeted by -309bps to 107.24% in 2024, then skyrocketed by 197bps to 103.87% in 2025, then plummeted by -186bps to 89.02% in 2026.
  • Per Business Quant, the three most recent readings for BIO's Net Margin are 89.02% (Q1 2026), 103.87% (Q4 2025), and 52.36% (Q3 2025).